CQENS Technologies Inc.
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
25.3 mo
Lead Asset
heat-hemp/cbd products (Preclinical)
Next Catalyst
—
Tracking 2 pipeline candidates for CQENS Technologies Inc. · Updated within the last hour.
Go deeper on CQENS Technologies Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on VAPA — live, with citations.
Score breakdownBased on 4 of 6 signals · derived from public data
25.3 months
D/E 0.22 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of March 31, 2026
Cash
$8.1M
Quarterly Burn
$979K
Free Cash Flow
-$979K
Total Liabilities
$2.2M
Shareholders Equity
$10.1M
Current Ratio
3.87
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| heat-hemp/cbd products | Preclinical |
| heat-not-burn system | Preclinical |
Commercialization & Governance
Commercialization
- Status
- Clinical-stage
- Has Revenue
- No
Frequently asked questions
What is CQENS Technologies Inc.'s lead drug candidate?
CQENS Technologies Inc.'s most advanced tracked candidate is heat-hemp/cbd products (Preclinical) for Hemp/CBD consumption.
What therapeutic areas does CQENS Technologies Inc. focus on?
CQENS Technologies Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on CQENS Technologies Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.